4th EACTS Mechanical Circulatory Support Summit

The 4th EACTS European Mechanical Circulatory Support Summit will run from 7-9 November 2019 THURSDAY 7 NOVEMBER (08:00-18:00) 08:00 Welcome 08:15 Session 1: A heart failure therapy continuum and transplantation conundrums Drugs, clips and LVADs: How to avoid a disconnect in heart failure therapies Tablets on top of LVADs - what is an optimal medical … Continue reading "4th EACTS Mechanical Circulatory Support Summit"

The 4th EACTS European Mechanical Circulatory Support Summit will run from 7-9 November 2019

THURSDAY 7 NOVEMBER (08:00-18:00)
08:00 Welcome
08:15 Session 1: A heart failure therapy continuum and transplantation conundrums
Drugs, clips and LVADs: How to avoid a disconnect in heart failure therapies
Tablets on top of LVADs – what is an optimal medical therapy after the implant?
Should we transplant stable LVAD patients – if and when to start the immunoreaction clock ticking
Lessons learned from the new UNOS allocation system
Direct ECMO to heart transplantation strategy, the European experience
Panel discussion
10:00 Break
 
10:30 EACTS MCS Lifetime Recognition Award
10:45 Session 2: Registries, guidelines and upcoming endeavors
Europe, Quo Vadis? – the EUROMACS report
Pearls and diamonds of the EACTS Expert Consensus on MCS
What has IMACS taught us about patient outcomes with durable MCS?
Inferences of the MEDAMACS on an optimal timing of an LVAD implant
How to preserve European global visibility and academic prominence? An insight of the EJCTS Editor-in-Chief
Panel discussion
12:15 Lunch
13:15 Session 3: Joint EACTS MCS & EURO-ELSO Scientific Symposium
Extended cardiopulmonary resuscitation (CPR) for refractory cardiac arrest
New arms for cardiopulmonary resuscitation: Light at the end of the tunnel?
Venoarterial (VA) ECLS in cardiogenic shock – still an ongoing debate
Different ECLS configurations in postcardiotomy shock
Direct transition from ECLS to durable LVADs
Panel discussion
14:45 Session 4: Changing paradigms in cardiogenic shock – New tools, groundbreaking strategies
Staged escalation of transaortic left ventricular unloading – a partial flow is good enough
ECLS de-escalation strategies with transaortic MCS – full flow ahead
Optimal device selection in cardiogenic shock – I do it my way
A quest towards longer-term transaortic MCS – promises and perils
Panel discussion
16:15 Break
16:45 Session 5: Novel integrated approaches and technologies in MCS space
Sensors in general and basic science
Wearables and AI algorithms
A true need for permanent wearables in LVADs? A new reality of unholstered device operation
A wealth of data and clinical implications of LVAD log files
What will the next generation LVAD look like? (Industry perspetive)
What will the next generation LVAD look like? (Industry perspetive)
Panel discussion
 
18:15 Close
 
Welcome reception (18:15-19:30)
FRIDAY 8 NOVEMBER (08:00-18:45)
08:00 Session 1: Perioperative challenges and evolving implant strategies
How should we optimise with redo cases? Tricks and caveats
Indications for intervention to manage aortic insufficiency – perioperative and on support
Durable LVAD exchanges and upgrades
Cardiopulmonary bypass in oblivion – ECLS facilitated LVAD implant
Cardiopulmonary bypass in oblivion – transaortic MCS facilitated LVAD implant
Off-pump LVAD implant. Is there a right time for a primetime?
Panel discussion
09:30 Session 2: Hemocompatibility – a new established entity in MCS landscape
Hemocompatibility related adverse events
Strokes and LVADs – characteristic features and treatment strategies
Indication of dependent and independent vitamin K antagonist (VKA) withdrawal in contemporary LVADs
The future of LVAD therapy in a spyglass of an expert hematologist
Panel discussion
10:40 Break
11:00 Session 3: The judgement of Paris: How do I choose the optimal pump for my patients?
12:00 Keynote: Integrative approach in overcoming residual risks of LVADs towards the equipoise with the heart transplant
12:30 Lunch
13:30 4th Rising Stars Quiz
14:30 Session 4: The right ventricle challenge
Longitudinal performance of the right ventricle through a magnifying glass
Right ventricular (RV) failure – isolated issue or a peril of interwoven complexity?
Evolving trends in treatment of early RV failure
Late right ventricular failure – now what?
Panel discussion
15:35 Session 5: Boon and bane of biventricular MCS solutions – when both ventricles are done
Chronic biventricular solution indications: Who, When, How?
RV dysfunction: Biventricular continuous flow pumps, total artificial heart (TAH) or paracorporeal devices – what is better?
Results with TAH are not superior to BiVAD in patients with severe RV dysfunction
New TAH alternatives: Pulsatile or continuous flow?
Panel discussion
16:30 Break
16:50 Session 6: From the new world: Unorthodox and creative solutions – How to get into or out of trouble
17:20 Session 7: Cardiac reverse remodeling and recovery in MCS – State of the art
Recovery on acute MCS – wait, wean or transition…When and how?
LVAD explantation for cardiac recovery – who and when?
The role of mitral regurgitation in sustainable LV recovery – fix it, clip later or simply ignore
Preliminary results of multicenter evaluation of plug use for LVAD explantation
The future of cardiac recovery in MCS space – 30 000 feet perspective
Panel discussion
18:45 Close
SATURDAY 9 NOVEMBER (08:00-14:00)
08:00 Session 1: Challenging populations and expanding horizons in heart failure landscape
Pitfalls of durable MCS in GUCH population
Surgical planning in complex anatomies
Optimised utilization of potential donor hearts – ex-vivo graft reconditioning
An ultimate frontier – DCD donors utilization for heart transplantation
Panel discussion
09:00 Session 2: Electrons, leads, devices and arrhythmia management in MCS
CIEDs in LVAD patients – PM, CRT, ICD
Transvenous lead extraction in LVAD patients – when, why and how?
Implantable cardiac monitoring systems in LVAD population
Supraventricular and ventricular arrhythmia management in MCS recipients
Panel discussion
10:00 Break
10:30 Session 3: Small improvements, a major impact?
Thrombus formation around inflow canula of CF-Pumps – interplay of a position and hemodynamics
Optimising inflow cannula position by 3D preop rendering
Background and outlook on the usage of cold atmospheric plasma (CAP) in medicine
CAP: An additive treatment option for critical wounds in cardiovascular surgery
Critical VAD exit site wounds – (Case series)
Panel discussion
11:30 Session 4: From the old world: Unorthodox and creative solutions – How to get into or out of trouble
12:30 Session 5: Update of current and upcoming devices
13:45 Closing Remarks

 

Programme subject to change

COURSE INFORMATION

Date/Duration
7-9 November 2019 (3 day course)

Location
Prague, Czech Republic
Please click HERE for more information

Chairmen
I Netuka, Prague; V Falk, Berlin and J Gummert, Bad Oeynhausen

Registration Fee
To be announced

Course fee includes lunch and refreshments on all days and the welcome reception on Thursday 7 November

Summit Format
Interactive lectures, live-in-a-box cases and keynote presentations

Target Audience
Cardiologists, heart failure cardiologists, emergency and ICU specialists (ECLS), cardiac surgeons, perfusionists, heart failure nurses and ventricular assist device (VAD) coordinators, medical industry (cardiac devices including ECMO development and production). Paediatric cardiologists and congenital heart disease surgeon.

Learning Objectives

  • Learn about how to find the right treatment for the right patient at the right time
  • Use of temporary MCS systems in emergency situations and in the ICU
  • Learning of recommendations for VAD use from major societies and from recently published guidelines
  • New surgical techniques for VAD implantation, as well as unusual solutions of complex surgical problems in VAD patients
  • How to avoid long-term complications during VAD treatment
  • Learn about shared care and the role of social media for VAD patients and caregivers
  • Learn about myocardial recovery in children and adults
  • Review and learn about the latest developments and perspectives in the VAD field